VRNA Verona Pharma plc

3.66
-0.49  -12%
Previous Close 4.15
Open 4.15
Price To Book 1.22
Market Cap 48,592,773
Shares 13,276,714
Volume 64,486
Short Ratio
Av. Daily Volume 84,017
Stock charts supplied by TradingView

NewsSee all news

  1. 2019 Annual Report and Accounts and Notice of AGM

    LONDON, March 16, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (NASDAQ:VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for

  2. Verona Pharma Reports Financial Results for the Full Year Ended December 31, 2019 and Provides Corporate Update

    Post-period end, reported positive top-line Phase 2b results with nebulized ensifentrine and senior management changes Conference Call Today at 9:00 am EST / 2:00 pm GMT LONDON, Feb. 27, 2020 (GLOBE NEWSWIRE) --

  3. Verona Pharma plc to Announce Financial Results for Full Year Ended December 31, 2019 and Provide Corporate Update

    LONDON, Feb. 21, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (NASDAQ:VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical company focused on respiratory diseases,  announces that it will report its

  4. Verona Pharma Announces Publication of Key Phase 2b COPD Data in Respiratory Research

    LONDON, Feb. 14, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (NASDAQ:VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces publication of Phase 2b

  5. Verona Pharma Announces Senior Management Changes

    Dr. David Zaccardelli appointed President and Chief Executive Officer Mark W. Hahn appointed Chief Financial Officer LONDON, Feb. 03, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (NASDAQ:VRNA) ("Verona

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2a data released March 2, 2018.
RPL554
Cystic fibrosis
Phase 2 trial did not meet primary endpoint - January 14, 2019.
RPL554
COPD
Phase 2 data met primary endpoint - August 5, 2019.
RPL554 DPI formulation
Maintenance treatment of COPD
Phase 3 trial to be initiated 2020.
Ensifentrine (RPL554) and tiotropium
Chronic obstructive pulmonary disease (COPD)
Phase 2 MDI single dose data due 1Q 2020.
Ensifentrine (RPL554) - Metered Dose Inhaler
Maintenance treatment of COPD

Latest News

  1. 2019 Annual Report and Accounts and Notice of AGM

    LONDON, March 16, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (NASDAQ:VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for

  2. Verona Pharma Reports Financial Results for the Full Year Ended December 31, 2019 and Provides Corporate Update

    Post-period end, reported positive top-line Phase 2b results with nebulized ensifentrine and senior management changes Conference Call Today at 9:00 am EST / 2:00 pm GMT LONDON, Feb. 27, 2020 (GLOBE NEWSWIRE) --

  3. Verona Pharma plc to Announce Financial Results for Full Year Ended December 31, 2019 and Provide Corporate Update

    LONDON, Feb. 21, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (NASDAQ:VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical company focused on respiratory diseases,  announces that it will report its

  4. Verona Pharma Announces Publication of Key Phase 2b COPD Data in Respiratory Research

    LONDON, Feb. 14, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (NASDAQ:VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces publication of Phase 2b

  5. Verona Pharma Announces Senior Management Changes

    Dr. David Zaccardelli appointed President and Chief Executive Officer Mark W. Hahn appointed Chief Financial Officer LONDON, Feb. 03, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (NASDAQ:VRNA) ("Verona

  6. Verona Pharma Reports Positive Top-line Data in 4 Week Phase 2b COPD Study with Nebulized Ensifentrine on Top of Tiotropium Therapy

    Primary endpoint met at all doses: ensifentrine produced clinically and statistically significant dose-dependent improvements in lung function Clinically relevant secondary endpoints met, including progressive and

  7. Verona Pharma to Report 4 Week Phase 2b COPD Dose-ranging Study Results with Nebulized Ensifentrine on Top of Tiotropium Therapy

    LONDON, Jan. 10, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (NASDAQ:VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical company focused on respiratory diseases, will release results on Monday,

  8. Verona Pharma Appoints David Moskowitz as Vice President, Capital Markets Strategy & Investor Relations

    LONDON, Jan. 07, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (NASDAQ:VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces the appointment of David

  9. Verona Pharma to Present at Jefferies 2019 London Healthcare Conference

    LONDON, Nov. 13, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (NASDAQ:VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that Jan-Anders Karlsson,

  10. Verona Pharma to Participate in Two Upcoming Institutional Investor Conferences in New York

    LONDON, Nov. 11, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (NASDAQ:VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that Jan-Anders Karlsson,

  11. Verona Pharma plc Operational Update and Financial Results for the Three and Nine Months Ended September 30, 2019

    Reported positive Phase 2 data with dry powder inhaler formulation Post period end, completed enrollment in Phase 2b study with nebulized ensifentrine as add-on to long-acting bronchodilator LONDON, Nov. 05, 2019

  12. Verona Pharma to Announce Financial Results for the Three and Nine Months Ended September 30, 2019 and Provide Clinical Development Update

    LONDON, Oct. 29, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (NASDAQ:VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical company focused on respiratory diseases, today announces that it will report

  13. Verona Pharma Completes Enrollment in Phase 2b Clinical Trial with Nebulized Ensifentrine in moderate-to-severe COPD

    LONDON, Oct. 17, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (NASDAQ:VRNA) ("Verona Pharma"), a biopharmaceutical company focused on respiratory diseases, announces that it has randomized the last patient in

  14. Verona Pharma to Present Phase 2 Symptom Data with Ensifentrine in COPD at CHEST 2019

    LONDON, Oct. 15, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (NASDAQ:VRNA) ("Verona Pharma"), a biopharmaceutical company focused on respiratory diseases, announces that it will present positive symptom data

  15. Verona Pharma to Present Phase 2 Data with Ensifentrine Dry Powder Inhaler Formulation in COPD at European Respiratory Society International Congress 2019

    LONDON, Sept. 19, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (NASDAQ:VRNA) ("Verona Pharma"), a biopharmaceutical company focused on respiratory diseases, announces that it will present positive interim data

  16. Verona Pharma to Present at H.C. Wainwright 21st Annual Global Investment Conference

    LONDON, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (NASDAQ:VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that Piers Morgan, CFO,